Ginkgo Bioworks Holdings, Inc. — Form 8-K Summary
Business context and reporting period
Ginkgo Bioworks Holdings, Inc. filed this Current Report on Form 8-K on March 28, 2022. The filing reports that the company issued a press release announcing financial results for the fourth quarter and year ended December 31, 2021.
Financial results and liquidity
The filing text provided does not include the underlying press release or clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics. Exhibit 99.1 is identified as the March 28, 2022 earnings press release, but its contents are not included in the source text.
Material changes versus the prior comparable period
The filing text does not provide sufficient financial data to assess changes versus the fourth quarter or full year of 2020.
Guidance, outlook, risks, and unusual items
No guidance, outlook, management commentary, risks, contingencies, or unusual items are described in the filing text provided. These matters may be included in the referenced Exhibit 99.1, which is not reproduced here.
Important facts to verify
- Obtain and review Exhibit 99.1 for the complete fourth-quarter and full-year 2021 financial results.
- Verify reported revenue, net loss, adjusted metrics, cash flow, cash and equivalents, debt, and liquidity.
- Review management’s 2022 guidance, operating outlook, and discussion of key risks and contingencies.
- Confirm any material year-over-year changes and any non-GAAP measures or unusual items disclosed in the earnings release.